Bristol-Myers Squibb Company Website

Bristol-Myers Squibb Company

NYSE-BMY

Income Statement
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

26,145

42,518

46,385

46,159

45,006

46,509

Total Revenues % Chg.

15.9%

62.6%

9.1%

-0.5%

-2.5%

2.9%

Cost of Goods Sold, Total

7,898

11,773

9,940

9,781

10,518

11,078

Gross Profit

18,247

30,745

36,445

36,378

34,488

35,431

Selling General & Admin Expenses, Total

4,969

7,618

7,655

7,703

7,678

7,891

R&D Expenses

6,066

10,048

10,195

9,201

9,112

9,200

Amortization of Goodwill and Intangible Assets

—

—

—

1,135

9,688

10,023

9,595

9,047

9,307

Other Operating Expenses, Total

12,170

27,354

27,873

26,499

25,837

26,398

Operating Income

6,077

3,391

8,572

9,879

8,651

9,033

Interest Expense, Total

-898

-1,381

-1,303

-1,205

-1,161

-1,551

Interest And Investment Income

464

121

39

171

449

522

Net Interest Expenses

-434

-1,260

-1,264

-1,034

-712

-1,029

Income (Loss) On Equity Invest.

—

-5

72

231

-108

-38

52

Currency Exchange Gains (Loss)

—

-13

23

32

148

160

89

Other Non Operating Income (Expenses)

1,496

1,528

1,708

1,818

2,079

1,912

EBT, Excl. Unusual Items

7,121

3,754

9,279

10,703

10,140

10,057

Restructuring Charges

-564

-538

-160

-144

-535

-816

Merger & Related Restructuring Charges

—

—

—

—

—

-1,072

-717

-564

-863

-326

-1,052

Gain (Loss) On Sale Of Investments

357

1,157

514

-693

-122

210

Gain (Loss) On Sale Of Assets

1,168

55

9

211

—

—

Asset Writedown

—

-15

—

—

-98

-107

-957

In Process R&D Expenses

—

—

—

—

—

—

-12,533

-1,159

-815

-913

-13,761

Legal Settlements

-77

194

-82

-178

-10

-13

Other Unusual Items

—

-1,943

1,757

261

-410

313

-87

EBT, Incl. Unusual Items

4,975

-6,871

8,098

7,713

8,440

-6,419

Income Tax Expense

1,515

2,124

1,084

1,368

400

109

Earnings From Continuing Operations

3,460

-8,995

7,014

6,345

8,040

-6,528

Minority Interest

-21

-20

-20

-18

-15

-13

Net Income

3,439

-9,015

6,994

6,327

8,025

-6,541

Net Income to Common Incl Extra Items

3,439

-9,015

6,994

6,327

8,025

-6,541

Net Income to Common Excl. Extra Items

3,439

-9,015

6,994

6,327

8,025

-6,541

Total Shares Outstanding

2,251

2,244

2,176

2,098

2,021

2,027

Weighted Avg. Shares Outstanding

1,705

2,258

2,221

2,130

2,069

2,033.5

Weighted Avg. Shares Outstanding Dil

1,712

2,258

2,245

2,146

2,078

2,033.5

EPS

2

-4

3.1

3

3.9

-3.2

EPS Diluted

2

-4

3.1

3

3.9

-3.2

EBITDA

7,798

13,824

19,329

20,161

18,420

19,048

Effective Tax Rate

30.5%

-30.9%

13.4%

17.7%

4.7%

-1.7%